IP Library Granted Patent US 11,883,091
Granted Patent B2
US 11,883,091 · App. 17/225,560 · Granted Jan 30, 2024

Systems and methods for improving sleep with therapeutic nasal treatment

Inventor: David Townley (County Clare, IE)
Assignee: Neurent Medical Limited
A61B18/148A61B2018/00327A61B2018/00434A61B2018/00583A61B2018/1467
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,883,091
App. No.
17/225,560
Granted
Jan 30, 2024
Kind
B2
Abstract

The invention generally relates to systems and methods for improving sleep by treating at least one of rhinitis, congestion, and/or rhinorrhea to thereby reduce or eliminate symptoms associated therewith, including, but not limited to, nasal congestion, coughing, sneezing, and nasal or throat irritation and itching.

Claims (19)

1. A method for improving a patient's sleep by treating at least one of rhinitis, congestion, and rhinorrhea within a sino-nasal cavity of a patient, the method comprising:

advancing a multi-segment end effector into the sino-nasal cavity of the patient, the multi-segment end effector being operably associated with a shaft of a treatment device and configured for delivering energy to one or more target sites within the sino-nasal cavity of the patient, the multi-segment end effector comprising a first segment that is spaced apart from a separate and distinct second segment along a length of the shaft, wherein each of the first and second segments is transformable between a retracted configuration and an expanded deployed configuration and comprises a respective architecture in the expanded deployed configuration, wherein the first segment comprises:

a first set of flexible support elements that each comprises an array of electrodes positioned at separate and discrete portions thereon and the first segment is transformable between a retracted configuration and an expanded deployed configuration, the first set of flexible support elements extend in a first outward direction relative to a longitudinal axis along which the shaft lies and are positioned within a first half of the first segment and cooperatively form an inwardly extending first concave shape when the first segment is in the expanded deployed configuration to complement anatomy at a first location within the nasal cavity; and

a second set of flexible support elements that each comprises an array of electrodes positioned at separate and discrete portions thereon and extend in a second outward direction relative to the longitudinal axis and substantially opposite the first outward direction and are positioned within a second half of the first segment and cooperatively form an inwardly extending second concave shape opposing the first concave shape when the first segment is in the expanded deployed configuration; and

deploying at least the first segment at a respective first location within the nasal cavity; and

delivering energy, via one or more of the electrodes, to one or more target sites at the first location within a sino-nasal cavity of the patient to disrupt multiple neural signals to, and/or result in local hypoxia of, mucus producing and/or mucosal engorgement elements, thereby reducing production of mucus and/or mucosal engorgement within a nose of the patient and reducing or eliminate one or more symptoms associated with at least one of rhinitis, congestion, and rhinorrhea to improve nasal breathability of the patient.

2. The method of claim 1 , wherein delivering energy results in ablation of targeted tissue at one or more positions at the first location to thereby disrupt the multiple neural signals to, and/or result in local hypoxia of, the mucus producing and/or mucosal engorgement elements within the nose.

3. The method of claim 2 , wherein the targeted tissue is associated with one or more target sites proximate or inferior to a sphenopalatine foramen.

4. The method of claim 3 , wherein energy is delivered at a level sufficient to therapeutically modulate postganglionic parasympathetic nerves innervating nasal mucosa at foramina and or microforamina of a palatine bone of the patient.

5. The method of claim 4 , wherein delivering energy causes multiple points of interruption of neural branches extending through foramina and microforamina of palatine bone.

6. The method of claim 2 , wherein ablation of targeted tissue causes thrombus formation within one or more blood vessels associated with mucus producing and/or mucosal engorgement elements within the nose.

7. The method of claim 6 , wherein the resulting local hypoxia of the mucus producing and/or mucosal engorgement elements results in decreased mucosal engorgement to thereby increase volumetric flow through a nasal passage of the patient.

8. The method of claim 2 , wherein the ablation is thermal ablation.

9. The method of claim 2 , wherein the ablation is caused by delivery of radiofrequency (RF) energy.

10. The method of claim 1 , wherein the end effector is advanced into the sino-nasal cavity under image guidance.

11. The method of claim 1 , wherein:

the first set of flexible support elements is arranged in a deployed configuration to fit around at least a portion of a middle turbinate at an anterior position relative to a lateral attachment and a posterior-inferior edge of the middle turbinate and position one or more electrodes into contact with one or more respective tissue locations associated with the middle turbinate; and

the second set of flexible support elements is arranged in a deployed configuration to position one or more electrodes into contact with one or more respective tissue locations in a cavity at a posterior position relative to the lateral attachment and posterior-inferior edge of the middle turbinate.

12. The method of claim 1 , wherein the one or more symptoms associated with at least one of rhinitis, congestion, and rhinorrhea are selected from the group consisting of nasal congestion, coughing, sneezing, and nasal or throat irritation and itching.

Assignments (2)
SECURITY INTEREST Recorded Oct 18, 2024
From: NEURENT MEDICAL LIMITED
To: CLARET EUROPEAN SPECIALTY LENDING COMPANY III, S.A R.L.
Reel/Frame 068942/0887 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2023
From: TOWNLEY, DAVID
To: NEURENT MEDICAL LIMITED
Reel/Frame 065827/0538 →
Continuity (2)
Provisional Application 63007584 · Apr 9, 2020
Related Publication 20210315634A1 · Oct 14, 2021
Cited By (17)
US 12,336,750 US 12,357,378 US 12,357,817 US 12,364,532 US 12,369,963 US 12,369,966 US 12,369,973 US 12,408,974 US 12,471,978 US 12,478,806 US 12,484,946 US 12,527,618 US 12,539,167 US 12,636,058 US 12,636,073 US 12,678,212 US 12,690,907